Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
https://doi.org/10.20996/1819-6446-2022-10-06
Abstract
The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According to the regulatory domestic and foreign documents, the use of direct oral anticoagulants in patients with atrial fibrillation has priority in comparison with vitamin K antagonists, since they have a predictable anticoagulant effect, the possibility of taking fixed doses without the need for routine anticoagulant monitoring, rapid onset and termination of action, relatively low potential for food and drug interactions. Direct oral anticoagulants are used for the prevention of thromboembolic complications in patients with atrial fibrillation, for the prevention of deep vein thrombosis in patients who have undergone surgery on the knee or hip joints, for emergency treatment and secondary prevention of deep vein thrombosis and pulmonary embolism. Alertness to side effects tends to focus on the likelihood of bleeding, with the possibility of other side effects of direct oral anticoagulants receiving less attention or going unnoticed. These mainly include liver damage, kidney damage and a number of other rare adverse reactions. The finding of isolated thrombocytopenia in patients taking direct oral anticoagulants may be associated with a high risk of life-threatening bleeding. The article analyzes published data on the occurrence of thrombocytopenia associated with the intake of direct oral anticoagulants, and presents a clinical case of thrombocytopenia while taking apixaban.
About the Authors
B. A. Tatarsky
North-West Federal Medical Research Center
Russian Federation
Russian Federation
Boris A. Tatarsky
St. Petersburg
N. V. Kazennova
North-West Federal Medical Research Center
Russian Federation
Russian Federation
Natalia V. Kazennova
St. Petersburg
References
1. Ghoshal K., Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Scientific World Journal 2014; 2014:781857.DOI:10.1155/2014/781857
2. Koupenova M., Clancy L., Corkrey H., et al. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. Circ Res. 2018;122:337-351.DOI:10.1161/ CIRCRESAHA. 117.310795
3. Connolly S., Ezekowitz M., Yusuf S., et al. Dabigatran versus Warfarin in Pa¬tients with Atrial Fibrillation. N Engl J Med 2009;361:1139-1151. DOI: 10.1056/NEJMoa0905561.
4. Patel M., Mahaffey K., Garg J., et al. Rivaroxaban versus Warfarin in Nonval-vular Atrial Fibrillation. N Engl J Med 2011;365:883-891. DOI: 10.1056/NEJMoa1009638
5. Granger C., Alexander J., McMurray J., et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981-992. DOI: 10.1056/NEJMoa1107039
6. Park J., Cha M.J., Choi Y.J., et al. Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation. Heart Rhythm 2019;16:197-203. DOI:10.1016/j.hrthm.2018.08.023
7. George J.N., Aster R.H. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology (Am Soc Hematol Educ Program). 2009:153-158. DOI: 10.1182/asheducation-2009.1.153
8. AL-Nouri Z.I., George J.N. Drug-induced thrombocytopenia. An updated systematic review, 2012. Drug Saf 2012;35:693-4. DOI: 10.2165/11633310-000000000-00000
9. Bonaccio M., Di Castelnuovo A., Costanzo S., et al. Age- and sex-based ranges of platelet count and causespecific mortality risk in an adult general population: prospective findings from the Moli-sani study. Platelets. 2018;29:312-315 DOI: 0.1080/09537104.2017.1411584
10. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) European Heart Journal 2020 Doi:10.1093/eurheartj/ ehaa612
11. Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373(3):252-261. DOI: 10.1056/NEJMcp1411910
12. Erdem G.U., Dogan M., Demirci N.S., et al. Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther. 2016;12(2):509-514. DOI: 10.4103/0973-1482.154056.
13. Fountain E.M., Arepally G.M. Etiology and complications of thrombocytopenia in hospitalized medical patients. J Thromb Thrombolysis. 2017;43:429-436 DOI: 10.1007/s11239-016-1467-8
14. Mc Carthty С., Steg P., Bhatt D. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J. 2017; 38: 3488-3492 DOI: 10.1093/eurheartj/ehx531
15. Yadav M., Genereux P., Giustino G., et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016;32:226-233. DOI: 10.1016/j.cjca.2015.05.020
16. Janion-Sadowska A., Papuga-Szela E., Łukaszuk R., et al. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia. Cardiovasc Pharmacol. 2018 Sep;72(3):153-160. DOI: 10.1097/FJC.0000000000000607
17. Pastori D., Antonucci E., Violi.F., et al. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. Journal of the American Heart Association. 2019;8(21):e012596. DOI 10.1161/JAHA.119.012596.
18. Michowitz Y., Klempfner R., Shlomo N., et al. Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy. 2019. PLOS ONE 14(11): e0224709. DOI:10.1371/journal.pone.0224709
19. Kalabalik J., Rattinger G., Sullivan J., et al. Use of nonvitamin K antagonist oral anticoagulants in special patient populations with nonvalvular atrial fibrillation: a review of the literature and application to clinical practice. Drugs 2015;75:979-998. DOI:10.1007/s40265-015-0405-y
20. Deidda A., Rapallo M., Sofia M., et al. Thrombocytopenia possibly induced by dabigatran: a case report. Aust J Pharm. 2015;3:1000170. DOI: 10.4172/2329-6887.1000170
21. Naranjo С.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther., 1981;30:239-45 DOI:10.1038/clpt.1981.154
22. Kang H.G., Lee S.J., Chung J.Y., et al. BMC Neurology 2017; 17:124-129 DOI: 10.1186/s12883-017-0900-8
23. U.S. Food and Drug Administration. 2018. Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS): fda.gov/drugs/questions-and-answersfdas-adverse-event-reporting-system-faers/july-september-2017-potential-signals-serious-risksnew-safe ty-information-identified-fda-adverse.
24. Mima Y., Sangatsuda Y., Yasaka M., et al. Acute thrombocytopenia after initiating anticoagulation with rivaroxaban Intern Med. 2014;53(21):2523-7. DOI: 10.2169/internalmedicine.53.2890
25. He X.Y., Bai Y. Acute thrombocytopenia after anticoagulation with rivaroxaban: A case report. World J Clin Cases. 2020;8(5):928-931. DOI: 10.12998/wjcc.v8.i5.928.
26. ELIQUIS (apixaban). Product Monograph. ELIQUIS (apixaban). 2019. Montreal, Canada H4S 0A4 www.bmscanada.ca
27. Snellgrove O. Case report: apixaban-induced thrombocytopenia. Clinical Case Reports 2017; 5(3): 268-269 DOI: 10.1002/ccr3.809
28. Sadaka S. Thrombocytopenia: A possible side effect of apixaban. Clin Case Rep. 2019;7:2543-2544 DOI: 10.1002/ccr3.2532
Review
For citations:
Tatarsky B.A., Kazennova N.V. Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review. Rational Pharmacotherapy in Cardiology. 2022;18(5):600-605. (In Russ.) https://doi.org/10.20996/1819-6446-2022-10-06
Views:
518
.jpg)
Email this article 